Sol-Gel Technologies (SLGL) Non Operating Income (2018 - 2026)
Sol-Gel Technologies' (SLGL) quarterly Non Operating Income came in at -$128000.0 in Q1 2026, up 50.96% year-on-year from -$84791.9 in Q1 2025, and down 130.19% on a QoQ basis from $424000.0 in Q4 2025.
Sol-Gel Technologies (SLGL) Non Operating Income (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 9 years of Non Operating Income data on file, last reported at -$128000.0 in Q1 2026.
- On a quarterly basis, Non Operating Income rose 50.96% year-over-year to -$128000.0 in Q1 2026; TTM through Mar 2026 was $1.0 million, a 26.8% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, down 1.6% from the prior year.
- Non Operating Income for Q1 2026 stood at -$128000.0, down from $424000.0 in the prior quarter.
- Over the last five years, Non Operating Income for SLGL reached as high as $596000.0 in Q3 2023 and fell as low as -$368000.0 in Q1 2024.
- Historically, Non Operating Income has averaged $164588.2 across 5 years, with a median of $346000.0 in 2025.
- On a YoY basis, Non Operating Income climbed as much as 1457.14% in 2022 and fell as far as 3555.56% in 2022.
- Year by year, Non Operating Income stood at $420000.0 in 2022, then surged by 35.95% to $571000.0 in 2023, then plunged by 55.69% to $253000.0 in 2024, then soared by 67.59% to $424000.0 in 2025, then plunged by 130.19% to -$128000.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were -$128000.0 in Q1 2026, $424000.0 in Q4 2025, and $346000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Sol-Gel Technologies | 234.04 Mn | 223.91 Mn | - | -128,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128,000.00 |
| Dec 31, 2025 | 424,000.00 |
| Sep 30, 2025 | 346,000.00 |
| Jun 30, 2025 | 380,000.00 |
| Mar 31, 2025 | -261,000.00 |
| Dec 31, 2024 | 253,000.00 |
| Sep 30, 2024 | 462,000.00 |
| Jun 30, 2024 | 352,000.00 |
| Mar 31, 2024 | -368,000.00 |
| Dec 31, 2023 | 571,000.00 |
| Sep 30, 2023 | 596,000.00 |
| Jun 30, 2023 | 557,000.00 |
| Mar 31, 2023 | -342,000.00 |
| Dec 31, 2022 | 420,000.00 |
| Sep 30, 2022 | 218,000.00 |
| Jun 30, 2022 | -329,000.00 |
| Mar 31, 2022 | -353,000.00 |
| Dec 31, 2021 | 73,000.00 |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | -9,000.00 |